Key result
Systemic thrombolysis with tPA improved hemodynamics and valve gradients in an 81-year-old man with cardiogenic shock from bioprosthetic valve thrombosis, though he later died from recurrent VT.
Why the study?
There is overall uncertainty regarding the optimal treatment of acute bioprosthetic valve thrombosis.
Case Report (n=1)
No takes yet. Share an insight, caveat, or question.
Thrombolysis succeeded in this bioprosthetic valve thrombosis shock case; leaves open optimal management strategy.
Chu et al. (2022) conducted a case report in Cardiogenic shock secondary to aortic bioprosthetic valve-in-valve thrombosis (n=1). Systemic thrombolysis (tissue plasminogen activator) was evaluated on Hemodynamic and echocardiographic improvement. Systemic thrombolysis with tPA improved hemodynamics and valve gradients in an 81-year-old man with cardiogenic shock from bioprosthetic valve thrombosis, though he later died from recurrent VT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: